We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+5.04%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.97B
AUM Growth
-$106M
Cap. Flow
-$271M
Cap. Flow %
-3.88%
Top 10 Hldgs %
34.81%
Holding
187
New
15
Increased
42
Reduced
87
Closed
11

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$28.5M
2
CLDX icon
Celldex Therapeutics
CLDX
+$26.8M
3
EXAS
Exact Sciences
EXAS
+$15.3M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$13.7M
5
CRL icon
Charles River Laboratories
CRL
+$6.89M

Top Sells

Rank Stock Value
1
RDUS
Radius Health, Inc.
RDUS
+$91.2M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$38.7M
3
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$24M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$19.3M
5
AXSM icon
Axsome Therapeutics
AXSM
+$16M

Sector Composition

Rank Sector Weight
1 Healthcare 99.34%
2 Industrials 0.59%
3 Energy 0.02%
4 Communication Services 0.01%
5 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABMD
51
DELISTED
Abiomed Inc
ABMD
$40.9M 0.59%
166,355
-3,154
-2% -$852K
ACCD
52
DELISTED
Accolade Inc
ACCD
$40.8M 0.59%
3,571,870
-63,016
-2% -$687K
GMED icon
53
Globus Medical
GMED
$10.5B
$38.6M 0.55%
647,163
-9,518
-1% -$573K
OM icon
54
Outset Medical
OM
$77.9M
$38.5M 0.55%
161,164
+6,049
+4% +$1.62M
HALO icon
55
Halozyme
HALO
$9.23B
$36.8M 0.53%
930,500
-40,800
-4% -$1.8M
EXAS
56
DELISTED
Exact Sciences
EXAS
$36.7M 0.53%
1,129,653
+371,630
+49% +$15.3M
TMO icon
57
Thermo Fisher Scientific
TMO
$198B
$36.6M 0.53%
72,144
+326
+0.5% +$182K
OMCL icon
58
Omnicell
OMCL
$2.09B
$36.1M 0.52%
414,284
-11,539
-3% -$1.21M
PEN icon
59
Penumbra
PEN
$12.5B
$36M 0.52%
189,774
-2,814
-1% -$452K
IDXX icon
60
Idexx Laboratories
IDXX
$44.8B
$35.5M 0.51%
108,822
-6,951
-6% -$2.55M
PFE icon
61
Pfizer
PFE
$143B
$33.6M 0.48%
767,300
-68,384
-8% -$3.32M
PACB icon
62
Pacific Biosciences
PACB
$447M
$31.6M 0.45%
5,439,551
-521,678
-9% -$2.99M
HRMY icon
63
Harmony Biosciences
HRMY
$1.96B
$29.1M 0.42%
657,188
-44,880
-6% -$2.19M
IQV icon
64
IQVIA
IQV
$34.4B
$29M 0.42%
160,227
-8,371
-5% -$1.83M
ESPR
65
DELISTED
Esperion Therapeutics
ESPR
$28.3M 0.41%
4,225,264
-10,000
-0.2% -$68.7K
ZBH icon
66
Zimmer Biomet
ZBH
$17.6B
$27.7M 0.4%
265,270
-817
-0.3% -$89.7K
MRSN
67
DELISTED
Mersana Therapeutics
MRSN
$27.6M 0.4%
163,304
+7,496
+5% +$1.22M
TMDX icon
68
Transmedics
TMDX
$2.56B
$27.3M 0.39%
653,814
+73,927
+13% +$3.22M
BEAM icon
69
Beam Therapeutics
BEAM
$2.83B
$27.2M 0.39%
571,721
-900
-0.2% -$51.3K
KZR
70
DELISTED
Kezar Life Sciences
KZR
$26.1M 0.37%
303,100
-400
-0.1% -$38.9K
VEEV icon
71
Veeva Systems
VEEV
$31.7B
$26M 0.37%
157,591
-11,185
-7% -$2.23M
LEGN icon
72
Legend Biotech
LEGN
$4.31B
$25.5M 0.37%
625,461
-4,978
-0.8% -$234K
MGNX icon
73
MacroGenics
MGNX
$285M
$25.3M 0.36%
7,325,514
– –
ATRC icon
74
AtriCure
ATRC
$1.77B
$25.1M 0.36%
642,447
+551
+0.1% +$25.2K
CSTL icon
75
Castle Biosciences
CSTL
$733M
$24.6M 0.35%
941,871
+812
+0.1% +$22.8K
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2022 Portfolio in Review

As of Q3 2022, Bellevue Group held 187 positions worth $6.97B, down 1.5% from $7.07B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Bellevue Group withdrew a net $271M in Q3 2022, closing 11 positions and reducing 87 holdings. Its most notable exit was Radius Health, Inc., an estimated $91.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Industrials and Energy.

Against the trend, Bellevue Group opened a new position in Zai Lab worth $1.28M.

  • Bellevue Group's largest Q3 2022 buy was Zai Lab: 36,600 shares worth $1.28M.
  • Bellevue Group added most to Revolution Medicines in Q3 2022, an estimated $28.5M increase.
  • Bellevue Group's biggest Q3 2022 reduction was Sarepta Therapeutics, cutting an estimated $38.7M.
  • Bellevue Group fully exited Radius Health, Inc. in Q3 2022, selling an estimated $91.2M.
  • Bellevue Group's ten largest holdings make up 35% of its $6.97B portfolio in Q3 2022.
  • Bellevue Group opened 15 new positions and closed 11 in Q3 2022.
  • Bellevue Group's portfolio value fell 1.5% quarter-over-quarter to $6.97B.

Based on Bellevue Group's 13F filing for Q3 2022, filed 14 Nov 2022.